Genetic polymorphism of drug metabolizing enzymes in association with risk of bile duct cancer

Asian Pacific Journal of Cancer Prevention

Volumn 13, Issue SUPPL.1, 2012, Pages 7-15

  Kukongviriyapan, Veerapol ^a  

^a KHON KAEN UNIVERSITY   (Thailand)

Author keywords

Cholangiocarcinoma; CYP1A2; Drug metabolizing enzymes; Glutathione S transferase; Pharmacogenetics

Indexed keywords

METHYLENETETRAHYDROFOLATE REDUCTASE (NADPH2);

BILE DUCT TUMOR; GENETIC POLYMORPHISM; GENETICS; HUMAN; INTRAHEPATIC BILE DUCT; RISK;

BILE DUCT NEOPLASMS; BILE DUCTS, INTRAHEPATIC; HUMANS; METHYLENETETRAHYDROFOLATE REDUCTASE (NADPH2); POLYMORPHISM, GENETIC; RISK;

EID: 84874047603     PISSN: 15137368     EISSN: 2476762X     Source Type: Journal    
DOI: 10.7314/APJCP.2012.13.KKSuppl.7     Document Type: Review

References (69)

1. Agundez JA (2008). Polymorphisms of human N-acetyltransferases and cancer risk. Curr Drug Metab, 9, 520-31.
2. Buranrat B, Chau-in S, Prawan A, Puapairoj A, Kukongviriyapan V (2012). NQO1 expression is correlated with the prognosis of cholangiocarcinoma. Asian Pac J Cancer Prev, 13, 127-32.
3. Buranrat B, Prawan A, Kukongviriyapan U, Kongpetch S, Kukongviriyapan V (2010). Dicoumarol enhances gemcitabine-induced cytotoxicity in high NQO1-expressing cholangiocarcinoma cells. World J Gastroenterol, 16, 2362-70.
4. Chen X, Wang H, Xie W, et al (2006). Association of CYP1A2 genetic polymorphisms with hepatocellular carcinoma susceptibility: a case-control study in a high-risk region of China. Pharmacogenet Genomics, 16, 219-227.
5. Cheng DM, Jiang YG, Huang CY, et al (2010). Polymorphism of MTHFR C677T, serum vitamin levels and cognition in subjects with hyperhomocysteinemia in China. Nutr Neurosci, 13, 175-82.
6. Chutinet A, Suwanwela NC, Snabboon T, et al (2012) Association between genetic polymorphisms and sites of cervicocerebral artery atherosclerosis. J Stroke Cerebrovasc Dis, 21, 379-85.
7. Dinkova-Kostova AT, Talalay P (2010). NAD(P)H:quinone acceptor oxidoreductase 1 (NQO1), a multifunctional antioxidant enzyme and exceptionally versatile cytoprotector. Arch Biochem Biophys, 501, 116-23.
8. Economopoulos KP, Sergentanis TN (2010). GSTM1, GSTT1, GSTP1, GSTA1 and colorectal cancer risk: a comprehensive meta-analysis. Eur J Cancer, 46, 1617-31.
9. Egan KM, Cai Q, Shu XO, et al (2004). Genetic polymorphisms in GSTM1, GSTP1, and GSTT1 and the risk for breast cancer: results from the Shanghai Breast Cancer Study and meta-analysis. Cancer Epidemiol Biomarkers Prev, 13, 197-204.
10. Eichelbaum M, Ingelman-Sundberg M, Evans WE (2006). Pharmacogenomics and individualized drug therapy. Annu Rev Med, 57, 119-37.
11. Escobar-Garcia DM, Del Razo LM, Sanchez-Pena LC, et al (2012). Association of glutathione S-transferase Omega 1-1 polymorphisms (A140D and E208K) with the expression of interleukin-8 (IL-8), transforming growth factor beta (TGF-beta), and apoptotic protease-activating factor 1 (Apaf-1) in humans chronically exposed to arsenic in drinking water. Arch Toxicol, 86, 857-68.
12. Garcia-Closas M, Malats N, Silverman D, et al (2005). NAT2 slow acetylation, GSTM1 null genotype, and risk of bladder cancer: results from the Spanish Bladder Cancer Study and meta-analyses. Lancet, 366, 649-59.
13. Ginsberg G, Smolenski S, Neafsey P, et al (2009). The influence of genetic polymorphisms on population variability in six xenobiotic-metabolizing enzymes. J Toxicol Environ Hlth B Crit Rev, 12, 307-33.
14. Guengerich FP, Johnson WW, Shimada T, et al (1998). Activation and detoxication of aflatoxin B1. Mutat Res, 402, 121-8.
15. Hayes JD, Flanagan JU, Jowsey IR (2005). Glutathione transferases. Annu Rev Pharmacol Toxicol, 45, 51-88.
16. Honjo S, Srivatanakul P, Sriplung H, et al (2005). Genetic and environmental determinants of risk for cholangiocarcinoma via Opisthorchis viverrini in a densely infested area in Nakhon Phanom, northeast Thailand. Int J Cancer, 117, 854-60.
17. IARC (1994). Infection with liver flukes (Opisthorchis viverrini, Opisthorchis felineus and Clonorchis sinensis). IARC Monogr Eval Carcinog Risks Hum, 61, 121-75.
18. Irigaray P, Belpomme D (2010). Basic properties and molecular mechanisms of exogenous chemical carcinogens. Carcinogenesis, 31, 135-48.
19. Kim D, Guengerich FP (2005). Cytochrome P450 activation of arylamines and heterocyclic amines. Annu Rev Pharmacol Toxicol, 45, 27-49.
20. Kim J, Cho YA, Kim DH, et al (2012). Dietary intake of folate and alcohol, MTHFR C677T polymorphism, and colorectal cancer risk in Korea. Am J Clin Nutr, 95, 405-12.
21. Klaassen CD (2007). Casarett and Doull's Toxicology: The Basic Science of Poisons, 7th ed. Mc-Graw-Hill, New York.
22. Ko KH, Kim NK, Yim DJ, et al (2006). Polymorphisms of 5,10-methylenetetrahydrofolate reductase (MTHFR C677T) and thymidylate synthase enhancer region (TSER) as a risk factor of cholangiocarcinoma in a Korean population. Anticancer Res, 26, 4229-33.
23. Kukongviriyapan V, Prawan A, Tassaneyakul W, Aiemsa-Ard J, Warasiha B (2003a). Arylamine N-acetyltransferase-2 genotypes in the Thai population. Br J Clin Pharmacol, 55, 278-81.
24. Kukongviriyapan V, Prawan A, Warasiha B, Tassaneyakul W and Aiemsa-ard J (2003b) Polymorphism of N-acetyltransferase 1 and correlation between genotype and phenotype in a Thai population. Eur J Clin Pharmacol 59:277-281.
25. Kurathong S, Lerdverasirikul P, Wongpaitoon V, Pramoolsinsap C, Kanjanapitak A, Varavithya W, Phuapradit P, Bunyaratvej S, Upatham ES and Brockelman WY (1985) Opisthorchis viverrini infection and cholangiocarcinoma. A prospective, case-controlled study. Gastroenterology 89:151-156.
26. Kushida H, Fujita K, Suzuki A, et al (2000). Metabolic activation of N-alkylnitrosamines in genetically engineered Salmonella typhimurium expressing CYP2E1 or CYP2A6 together with human NADPH-cytochrome P450 reductase. Carcinogenesis, 21, 1227-32.
27. Landi MT, Sinha R, Lang NP, Kadlubar FF (1999). Chapter 16. Human cytochrome P4501A2. IARC Sci Pub, 148, 173-95.
28. Le Marchand L, Donlon T, Kolonel LN, Henderson BE, Wilkens LR (2005a) Estrogen metabolism-related genes and breast cancer risk: the multiethnic cohort study. Cancer Epidemiol Biomarkers Prev, 14, 1998-2003.
29. Le Marchand L, Wilkens LR, Kolonel LN, Henderson BE (2005b). The MTHFR C677T polymorphism and colorectal cancer: the multiethnic cohort study. Cancer Epidemiol Biomarkers Prev, 14, 1198-203.
30. Li D, Jiao L, Li Y, et al (2006). Polymorphisms of cytochrome P4501A2 and N-acetyltransferase genes, smoking, and risk of pancreatic cancer. Carcinogenesis, 27, 103-111.
31. Li W, Yue W, Zhang L, et al (2012). Polymorphisms in GSTM1, CYP1A1, CYP2E1, and CYP2D6 are associated with susceptibility and chemotherapy response in non-small-cell lung cancer patients. Lung, 190, 91-8.
32. Lo HW, Ali-Osman F (2007). Genetic polymorphism and function of glutathione S-transferases in tumor drug resistance. Curr Opin Pharmacol, 7, 367-74.
33. Loeb LA, Harris CC (2008). Advances in chemical carcinogenesis: a historical review and prospective. Cancer Res, 68, 6863-72.
34. Marahatta SB, Punyarit P, Bhudisawasdi V, Paupairoj A, Wongkham S, Petmitr S (2006). Polymorphism of glutathione S-transferase omega gene and risk of cancer. Cancer Lett, 236, 276-81.
35. Mazaki T, Masuda H, Takayama T (2011). Polymorphisms and pancreatic cancer risk: a meta-analysis. Eur J Cancer Prev, 20, 169-83.
36. Menzel HJ, Sarmanova J, Soucek P, et al (2004). Association of NQO1 polymorphism with spontaneous breast cancer in two independent populations. Br J Cancer, 90, 1989-94.
37. Mitacek EJ, Brunnemann KD, Suttajit M, et al (2008). Geographic distribution of liver and stomach cancers in Thailand in relation to estimated dietary intake of nitrate, nitrite, and nitrosodimethylamine. Nutr Cancer, 60, 196-203.
38. Mo Z, Gao Y, Cao Y, Gao F, Jian L (2009). An updating meta-analysis of the GSTM1, GSTT1, and GSTP1 polymorphisms and prostate cancer: a HuGE review. Prostate, 69, 662-88.
39. Modugno F, Knoll C, Kanbour-Shakir A, Romkes M (2003). A potential role for the estrogen-metabolizing cytochrome P450 enzymes in human breast carcinogenesis. Breast Cancer Res Treat, 82, 191-7.
40. Moysich KB, Shields PG, Freudenheim JL, et al (1999). Polychlorinated biphenyls, cytochrome P4501A1 polymorphism, and postmenopausal breast cancer risk. Cancer Epidemiol Biomarkers Prev, 8, 41-4.
41. Nakachi K, Imai K, Hayashi S, Kawajiri K (1993). Polymorphisms of the CYP1A1 and glutathione S-transferase genes associated with susceptibility to lung cancer in relation to cigarette dose in a Japanese population. Cancer Res, 53, 2994-9.
42. Nakajima M, Yokoi T, Mizutani M, et al (1999) Genetic polymorphism in the 5'-flanking region of human CYP1A2 gene: effect on the CYP1A2 inducibility in humans. J Biochem, 125, 803-8.
43. Nebert DW, Dalton TP (2006). The role of cytochrome P450 enzymes in endogenous signalling pathways and environmental carcinogenesis. Nat Rev Cancer, 6, 947-60.
44. Osawa Y, Osawa KK, Miyaishi A, et al (2007). NAT2 and CYP1A2 polymorphisms and lung cancer risk in relation to smoking status. Asian Pac J Cancer Prev, 8, 103-8.
45. Parkinson A (1996). Biotransformation of xenobiotics, in Casarett and Doull's Toxicology: The basic science of poisons (Kalaassen CD ed) pp 113-186, McGraw-Hill, New York.
46. Peamkrasatam S, Sriwatanakul K, Kiyotani K, et al (2006). In vivo evaluation of coumarin and nicotine as probe drugs to predict the metabolic capacity of CYP2A6 due to genetic polymorphism in Thais. Drug Metab Pharmacokinet, 21, 475-84.
47. Pongstaporn W, Pakakasama S, Sanguansin S, Hongeng S, Petmitr S (2009). Polymorphism of glutathione S-transferase Omega gene: association with risk of childhood acute lymphoblastic leukemia. J Cancer Res Clin Oncol, 135, 673-8.
48. Powers HJ (2005). Interaction among folate, riboflavin, genotype, and cancer, with reference to colorectal and cervical cancer. J Nutr, 135, 2960-6.
49. Prawan A, Kukongviriyapan V, Tassaneeyakul W, Pairojkul C, Bhudhisawasdi V (2005). Association between genetic polymorphisms of CYP1A2, arylamine N-acetyltransferase 1 and 2 and susceptibility to cholangiocarcinoma. Eur J Cancer Prev, 14, 245-50.
50. Safarinejad MR, Safarinejad S, Shafiei N (2011). Association of genetic polymorphism of glutathione S-transferase (GSTM1, GSTT1, GSTP1) with bladder cancer susceptibility. Urol Oncol, 10, 1016.
51. Schmuck EM, Board PG, Whitbread AK, et al (2005). Characterization of the monomethylarsonate reductase and dehydroascorbate reductase activities of Omega class glutathione transferase variants: implications for arsenic metabolism and the age-at-onset of Alzheimer's and Parkinson's diseases. Pharmacogenet Genomics, 15, 493-501.
52. Shimada T (2006). Xenobiotic-metabolizing enzymes involved in activation and detoxification of carcinogenic polycyclic aromatic hydrocarbons. Drug Metab Pharmacokinet, 21, 257-76.
53. Shin HR, Oh JK, Masuyer E, et al (2010). Epidemiology of cholangiocarcinoma: an update focusing on risk factors. Cancer Sci, 101, 579-85.
54. Siegel D, McGuinness SM, Winski SL, Ross D (1999). Genotype-phenotype relationships in studies of a polymorphism in NAD(P)H:quinone oxidoreductase 1. Pharmacogenetics, 9, 113-21.
55. Siegel D, Ross D (2000). Immunodetection of NAD(P) H:quinone oxidoreductase 1 (NQO1) in human tissues. Free Radic Biol Med, 29, 246-53.
56. Sim E, Lack N, Wang CJ, et al (2008). Arylamine N-acetyltransferases: structural and functional implications of polymorphisms. Toxicology, 254, 170-83.
57. Songserm N, Promthet S, Sithithaworn P, et al (2012). Risk factors for cholangiocarcinoma in high-risk area of Thailand: role of lifestyle, diet and methylenetetrahydrofolate reductase polymorphisms. Cancer Epidemiol, 36, 89-94.
58. Srivatanakul P, Ohshima H, Khlat M, et al (1991a). Endogenous nitrosamines and liver fluke as risk factors for cholangiocarcinoma in Thailand. IARC Sci Pub, 105, 88-95.
59. Srivatanakul P, Parkin DM, Jiang YZ, et al (1991b). The role of infection by Opisthorchis viverrini, hepatitis B virus, and aflatoxin exposure in the etiology of liver cancer in Thailand. A correlation study. Cancer, 68, 2411-7.
60. Suzuki H, Morris JS, Li Y, et al (2008). Interaction of the cytochrome P4501A2, SULT1A1 and NAT gene polymorphisms with smoking and dietary mutagen intake in modification of the risk of pancreatic cancer. Carcinogenesis, 29, 1184-91.
61. Thamavit W, Bhamarapravati N, Sahaphong S, Vajrasthira S, Angsubhakorn S (1978). Effects of dimethylnitrosamine on induction of cholangiocarcinoma in Opisthorchis viverrini-infected Syrian golden hamsters. Cancer Res 38:4634-4639.
62. Walker K, Ginsberg G, Hattis D, et al (2009). Genetic polymorphism in N-Acetyltransferase (NAT): Population distribution of NAT1 and NAT2 activity. J Toxicol Environ Hlth B Crit Rev, 12, 440-72.
63. Wang H, Tan W, Hao B, et al (2003). Substantial reduction in risk of lung adenocarcinoma associated with genetic polymorphism in CYP2A13, the most active cytochrome P450 for the metabolic activation of tobacco-specific carcinogen NNK. Cancer Res, 63, 8057-61.
64. White DL, Li D, Nurgalieva Z, El-Serag HB (2008) Genetic variants of glutathione S-transferase as possible risk factors for hepatocellular carcinoma: a HuGE systematic review and meta-analysis. Am J Epidemiol, 167, 377-89.
65. Williams JA, Stone EM, Fakis G, et al (2001). N-Acetyltransferases, sulfotransferases and heterocyclic amine activation in the breast. Pharmacogenetics, 11, 373-88.
66. Yang FY, Guan QK, Cui YH, et al (2012). NAD(P)H quinone oxidoreductase 1 (NQO1) genetic C609T polymorphism is associated with the risk of digestive tract cancer: a meta-analysis based on 21 case-control studies. Eur J Cancer Prev, 21, 42-1.
67. Yu H, Liu H, Wang LE, Wei Q (2012). A functional NQO1 609C>T polymorphism and risk of gastrointestinal cancers: a meta-analysis. PLoS One, 7, 30566.
68. Zeekpudsa P, Prawan A, Kukongviriyapan V, Bhudhisawasdi V (2009). Genetic polymorphism of NAD(P) H-quinone reductase-1 in Thais and its association with cholangiocarcinoma, in 3rd Asian Pacific Regional Meeting International Society for the Study of Xenobiotics p 75, Bangkok, Thailand.
69. Zhu LR, Thomas PE, Lu G, et al (2006). CYP2A13 in human respiratory tissues and lung cancers: an immunohistochemical study with a new peptide-specific antibody. Drug Metab Dispos, 34, 1672-6.